Boostrix vaccine

GPTKB entity

Statements (60)
Predicate Object
gptkbp:instance_of gptkb:vaccine
gptkbp:administered_by injection
gptkbp:approves gptkb:2005
gptkbp:available_in multiple countries
gptkbp:average_temperature 2 to 8 degrees Celsius
gptkbp:clinical_trial Phase III
gptkbp:clinical_use booster vaccination
gptkbp:contains gptkb:diphtheria_toxoid
gptkb:tetanus_toxoid
acellular pertussis antigens
gptkbp:contraindication severe allergic reaction to vaccine components
gptkbp:dosage_form single-dose vial
recommended every 10 years
gptkbp:formulation liquid suspension
https://www.w3.org/2000/01/rdf-schema#label Boostrix vaccine
gptkbp:ingredients gptkb:diphtheria_toxoid
gptkb:tetanus_toxoid
pertussis antigens
gptkbp:is_effective_against high efficacy against diphtheria
high efficacy against pertussis
high efficacy against tetanus
gptkbp:is_recommended_by gptkb:CDC
gptkb:WHO
gptkbp:is_recommended_for adults
adolescents
gptkbp:is_vulnerable_to updated periodically
varies by location
public health programs
refrigerated
FDA approved
ongoing studies
healthcare provider
EMA approved
adverse effects monitoring
combination vaccine
available through pharmacies
reduces morbidity and mortality
developed from DTP vaccine
reduces incidence of disease
single dose for adolescents and adults
gptkbp:manufacturer gptkb:Glaxo_Smith_Kline
gptkbp:market ongoing
gptkbp:route_of_administration intramuscular
gptkbp:safety_features generally well tolerated
gptkbp:side_effect fatigue
headache
muscle pain
fever
recommended
pain at injection site
gptkbp:target_audience adolescents and adults
gptkbp:trade gptkb:Boostrix
gptkbp:used_for prevention of diphtheria
prevention of pertussis
prevention of tetanus
gptkbp:vaccine_category gptkb:Tdap_vaccine
gptkbp:vaccine_funding covered by insurance plans
gptkbp:vaccine_information patient information leaflet
gptkbp:bfsParent gptkb:Boostrix
gptkbp:bfsLayer 5